Michael Gelband’s Genomic Health, Inc. GHDX Stock Holding History

Michael Gelband’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,163	Closed	-$242K	–	1779
2019 Q2	$242K	Buy	+4,163	New	+$247K	0.01%	808

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Michael Gelband's GHDX Position: Q3 2019 in Review

Michael Gelband sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 4,163 shares — an estimated $242K sold.

Michael Gelband first reported a position in GHDX in Q2 2019 and held it in 1 quarter. The position peaked at $242K in Q2 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

Michael Gelband reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
Michael Gelband sold 4,163 Genomic Health, Inc. shares in Q3 2019, an estimated $242K.
Michael Gelband first reported a position in Genomic Health, Inc. in Q2 2019 and held it in 1 quarter.
Michael Gelband's Genomic Health, Inc. position peaked at $242K in Q2 2019.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on ExodusPoint Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.